Axio BioPharma Unveils Advanced Protein Manufacturing Services
Axio BioPharma, recognized for its innovative breakthroughs in the biopharmaceutical sector, is excited to announce the launch of its protein manufacturing services. The focus is on producing high-quality monoclonal antibodies, a move designed to accelerate the development of biologics.
Committed to Enhancing Biopharmaceutical Solutions
As the need for recombinant protein manufacturing continues to rise, Axio BioPharma has strategically positioned itself within Forward BIOLABS. The company's goal is to meet the evolving demands of the biopharmaceutical industry. With facilities built to efficiently handle a variety of projects, Axio BioPharma ensures clients receive top-notch service.
Innovative Method for Monoclonal Antibody Production
“At Axio BioPharma, we aim to be the preferred partner for organizations wanting to develop groundbreaking biologics,” shared Justin Byers, the Founder and CEO. He highlighted that their advanced manufacturing techniques play a crucial role in hastening the development of essential therapies.
Experienced Team Delivering Exceptional Results
Specializing in research-grade manufacturing of monoclonal antibodies, Axio BioPharma is well-equipped for small-scale production, ranging from 50 mL to 2 L. Their dedicated team tackles unique program challenges, ensuring reliable and efficient outcomes for every project.
Flexible Production Capabilities
Besides focusing on monoclonal antibodies, Axio BioPharma proudly supports the production of mammalian-expressed proteins, which adds flexibility to meet varying needs in research and development programs. This scalability enables them to provide tailored solutions that enhance clients' biologics pipelines, making the production process more streamlined and responsive to client demands.
Plans for Future Expansion
As they look toward the future, Axio BioPharma is preparing to expand its capabilities even further, with plans to integrate GMP (Good Manufacturing Practice) mammalian manufacturing by early 2028. This important development will allow Axio BioPharma to assist clients throughout their developmental phases, from initial research to clinical manufacturing, ultimately advancing the path to life-saving therapies.
Addressing Market Challenges
“We blend our expertise with adaptable production scales to support clients through various research stages,” Byers noted. Aware of the challenges involved in bringing new therapies to fruition, the company is dedicated to making the process quicker and more efficient. The upcoming GMP services will offer clients a more thorough level of support.
About Axio BioPharma
Axio BioPharma exists as a Contract Development and Manufacturing Organization (CDMO) that plays a key role in revolutionizing biopharmaceutical manufacturing. Their dedication to producing high-quality recombinant proteins, with an emphasis on mammalian-expressed proteins and monoclonal antibodies, sets them apart. Based in Madison, Axio BioPharma strives to minimize the time it takes to deliver life-saving therapies through strategic partnerships in the biopharma industry.
For those interested in learning more about Axio BioPharma's innovative services and partnership opportunities, the company invites you to reach out directly.
Media Contact:
Justin Byers
Founder & CEO
Media inquiries can be directed through the company's official communication channels.
Frequently Asked Questions
What services does Axio BioPharma offer?
Axio BioPharma focuses on recombinant protein manufacturing, especially monoclonal antibodies, to support biopharmaceutical development.
Where is Axio BioPharma located?
Axio BioPharma is based at Forward BIOLABS, which provides a great environment for biopharmaceutical research and manufacturing.
What are the company's plans for future growth?
The company plans to roll out GMP mammalian manufacturing capabilities by early 2028 to offer more comprehensive support to clients.
Who leads Axio BioPharma?
Justin Byers is the Founder and CEO of Axio BioPharma, steering the company's innovative initiatives in biopharmaceutical manufacturing.
How does Axio BioPharma maintain quality in its offerings?
With a commitment to research-grade manufacturing and a skilled team, Axio BioPharma emphasizes high standards and efficiency throughout its production processes.
